MELBOURNE, Australia--(BUSINESS WIRE)--Biotechnology company Avexa Limited (ASX:AVX) announced today that it will present at the 2008 BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 3:30 PM EST at the Waldorf-Astoria hotel in New York. Dr Julian Chick, CEO will provide a general update together with an overview of data from the Phase 2b clinical trial of apricitabine (ATC), the Company’s lead anti-HIV drug candidate, recently presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2008), held in Boston on February 4, 2008.
